Palo Alto, CA – According to filings with the U.S. Securities and Exchange Commission, Base5 Genomics is raising $4,210,921.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Solomon Endlich played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Base5 Genomics
At Base5 Genomics our team is dedicated to empowering the medical community to give patients the personalized treatment they need. Sequencing solutions that reveal the full genomic diversity in humans and other organisms.

To learn more about Base5 Genomics, visit http://www.b5genomics.com/

Contact:
Solomon Endlich, Chief Executive Officer
707-696-4333
https://www.linkedin.com/in/solomon-endlich-56200113/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved